Scoliosis is a medical condition characterized by the abnormal curvature of the spine, often in a sideways direction. Treatment approaches for scoliosis can vary based on factors such as the severity of the condition, the age of the patient, and the specific characteristics of the spinal curvature. While surgical intervention may be necessary in severe cases, non-surgical treatments are also employed, especially for less severe cases, particularly in adolescents.
Latest Scoliosis Treatment Companies Update
July 2023: The MARVELTM Growing Rod System, developed by industry leader Globus Medical, Inc. for use by children with early-onset scoliosis, allows for growth while providing correction through the use of minimally invasive distraction techniques. The system is set to be commercially available to patients in the near future. The MARVELTM growing rods include a robust gear mechanism that efficiently and reliably lengthens the rods across a wide expansion range of 40 or 60 mm, and the rods' PEEK polymer bearing surfaces reduce wear. To lengthen each rod, a minimally invasive approach is used, which involves making a tiny incision to allow the driver access while minimizing damage to soft tissues. One of the most difficult disorders for children spine surgeons to treat is early onset scoliosis because of the necessity to balance development with curve correction.
June 2023: Pediatric patients three years of age and up with growth failure caused by insufficient secretion of endogenous growth hormone can now take NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, according to an announcement made by Pfizer Inc. and OPKO Health Inc. in June 2023. In August 2023, NGENLA is anticipated to be approved for prescription in the United States. We are thrilled to bring this next-generation treatment to patients in the United States. Pfizer has been dedicated to supporting individuals with growth hormone deficiency for over 30 years, starting with the delivery of a medicine that has been standard of care. Our goal is to continue helping children with this rare growth disorder reach their full potential.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)